IPSCO Tubulars IPSC 深 滬
等待開盤 09-06 09:30:00 美东时间
0.5047
+0.026
+5.41%
華盛通- 最 高0.5098
- 今 開0.49
- 成交量 54.80万股
- 最 低 0.4862
- 昨 收 0.4788
- 總市值 4360.06万
- 52周最高 1.8599
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 0.3418
- 委 比 -96.88%
- 總股本 8638.91万
- 歷史最高 32.899
- 量 比 0.84
- 振 幅 4.93%
- 歷史最低 0.3418
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
08-28 21:07
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
Century Therapeutics' CEO Brent Pfeiffenberger will present at the H.C. Wainwright Global Investment Conference on September 9-10, 2025, in New York. An on-demand webcast of the presentation will be available on September 5, 2025, on the company’s website. Century Therapeutics is a biotech company developing iPSC-derived cell therapies for autoimmune diseases and cancers, focusing on off-the-shelf therapies to expand patient access.
08-22 12:00
Shineco Launches Blockchain-Driven Cell Technology Division to Speed Global Stem Cell Product Distribution
Shineco Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business
08-13 18:33
Century Therapeutics Announces Major Workforce Reduction
An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July...
07-08 04:29
百诚医药：6月30日接受机构调研，财通证券、方正富邦基金等多家机构参与
证券之星消息，2025年7月4日百诚医药（301096）发布公告称公司于2025年6月30日接受机构调研，财通证券、方正富邦基金、德邦基金、宝盈基金、运舟资本、国联基金、惠通基金、青骊投资、国寿安保基金、招商基金、弘尚资产、光大保德信、上海开思私募基金、中金公司、摩根基金参与。
07-04 19:01
Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
Century Therapeutics to Present Two Abstracts at EULAR 2025 Congress The company will highlight data on its iPSC-derived cell therapy pipeline for autoimmune diseases and cancer. Abstracts include CNTY-101, a CD19-targeting CAR-NK product, and generation of CAR-NK, γδ CAR-T, and αβ CAR-T cells. Presentations by Hongxia Zhang, Ph.D. and Jonathan Kurtz, Ph.D. will occur on June 12. Additional materials will be available on the company’s website p...
05-28 20:01
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6
Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $7 to $6.
05-17 06:33
Century Therapeutics Q1 EPS $0.89 Beats $0.16 Estimate, Sales $109.16M Beat $49.55M Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.16 by 456.25 percent. This is a 297.78 percent increase over losses of $(0.45) per share
05-16 04:16
